BridgeBio Pharma (FRA:2CL) Change In Inventory : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Change In Inventory?

BridgeBio Pharma's change in inventory for the quarter that ended in Dec. 2024 was €0.0 Mil. It means BridgeBio Pharma's inventory stayed the same from Sep. 2024 to Dec. 2024 .

BridgeBio Pharma's change in inventory for the fiscal year that ended in Dec. 2024 was €0.0 Mil. It means BridgeBio Pharma's inventory stayed the same from Dec. 2023 to Dec. 2024 .

BridgeBio Pharma's Total Inventories for the quarter that ended in Dec. 2024 was €0.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BridgeBio Pharma's Days Inventory for the quarter that ended in Dec. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BridgeBio Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

BridgeBio Pharma Change In Inventory Historical Data

The historical data trend for BridgeBio Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Change In Inventory Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

BridgeBio Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

BridgeBio Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

BridgeBio Pharma (FRA:2CL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BridgeBio Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	1.99	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BridgeBio Pharma's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	1.99	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BridgeBio Pharma's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	5.617
	=	0.00

BridgeBio Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines